Takeda Pharmaceutical International AG Singapore
Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly innovative medicines. In Singapore, Takeda has been a key healthcare partner contributing in the therapeutic areas of oncology, plasma-derived therapies and rare diseases.
See below for the Latest Takeda Pharmaceutical International AG Singapore News, Analysis, Profit Results, Share Price Information, and Commentary.
Why rare disease policies are critical to ensure equitable access to treatment for rare disease communities in Southeast Asia
Why rare disease policies are critical to ensure equitable access to treatment for rare disease communities in Southeast Asia
Patient empowerment and policy change were emphasised as key points to address during the 2nd Southeast Asia Rare Disease Summit.
Takeda Pharmaceuticals secures Healthcare Asia Pharma Awards for Patient Assistance Programme
The affordability-based programme is designed to be equitable and sustainable.
Most Read
1. Global endoscopic closure devices market to grow by $825.7m by 2029 2. Disa unit inks licensing agreement to commercialise cataract screening device 3. NHG names new Chairman, Medical Board of Khoo Tech Puat Hospital 4. Qatar develops advanced occupational and environmental medicine programme 5. New Communicable Diseases Agency to be set up in first half of 2025Resource Center
Read Here
Advertise
Sign Up
Awards
Apr
10
Events
Event News
He discussed the pressing challenges and transformative solutions shaping the future of healthcare in the Asia Pacific.
